Publication of more detail surrounding the partial approval of Novartis' CAR-T therapy KYMRIAH (tisagenlecleucel) has confirmed an ad-hoc pre-election process, disagreement between the company and MSAC, and the fact funding is for two years with the process to be run all over again. …
Latest Video
New Stories
-
The 'Dispatched' week in review podcast - 7 March
March 7, 2025 - - Podcast -
Kosi Challenge fundraising total races past $400,000 as Pharma Cup teams add to totals
March 7, 2025 - - Latest News -
Women twice as likely as men to skip a prescription because of cost
March 7, 2025 - - Latest News -
Omico welcomes new government investment in precision medical trial
March 7, 2025 - - Latest News -
Five pharma companies recognised amongst Australia’s Best Workplaces for Women
March 7, 2025 - - Latest News -
Version 20 of Medicines Australia code takes PR back to the future
March 7, 2025 - - Latest News -
AusBiotech and Medicines Australia gather for International Women’s Day
March 6, 2025 - - Latest News